Collegium Pharmaceutical
COLL
75 hedge funds and large institutions have $273M invested in Collegium Pharmaceutical in 2017 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 28 increasing their positions, 17 reducing their positions, and 7 closing their positions.
65% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 17
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
4.74% more ownership
Funds ownership: 83.33% → 88.06% (+4.7%)
4% more funds holding
Funds holding: 72 → 75 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less capital invested
Capital invested by funds: $307M → $273M (-$33.9M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $506K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$9.08M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$5.44M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
+$2.37M |
| 4 |
JGC
J. Goldman & Co
New York
|
+$2.33M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$2.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Pier Capital
Stamford,
Connecticut
|
-$4.95M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.75M |
| 3 |
CCM
Cadian Capital Management
New York
|
-$2.18M |
| 4 |
BCMNY
Buckingham Capital Management (New York)
New York
|
-$1.16M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$654K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PC
76
Pier Capital
Stamford,
Connecticut
| – | -$4.95M | -395,658 | Closed |
|
|
77
Fidelity Investments
Boston,
Massachusetts
| – | -$2.75M | -220,043 | Closed |
|
|
SSA
78
Schonfeld Strategic Advisors
New York
| – | -$537K | -42,931 | Closed |
|
|
HCM
79
Highbridge Capital Management
New York
| – | -$434K | -34,741 | Closed |
|
|
BFS
80
Bradley Foster & Sargent
Hartford,
Connecticut
| – | -$403K | -32,185 | Closed |
|
81
Group One Trading
Chicago,
Illinois
| – | -$31K | -2,500 | Closed |
|
|
GAM
82
Gemmer Asset Management
Walnut Creek,
California
| – | -$1K | -100 | Closed |
|
COLL Hedge Fund Activity: Q3 2017 in Review
75 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q3 2017, worth a combined $273M — down 11% from $307M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new COLL positions and 7 closed out — a net gain of 3 holders — while 28 added to existing stakes and 17 trimmed.
The largest buyer was Millennium Management, adding an estimated $9.08M. The largest seller was Pier Capital, exiting entirely with an estimated $4.95M sold.
- 75 institutional investors held Collegium Pharmaceutical (COLL) as of Q3 2017, up from 72 in Q2 2017.
- Funds reported $273M of Collegium Pharmaceutical stock for Q3 2017, down 11% quarter-over-quarter.
- 10 funds opened new Collegium Pharmaceutical positions in Q3 2017 and 7 closed out, a net change of +3 holders.
- The largest Collegium Pharmaceutical buyer in Q3 2017 was Millennium Management, an estimated $9.08M added.
- The largest Collegium Pharmaceutical seller in Q3 2017 was Pier Capital, an estimated $4.95M sold.
Based on aggregated 13F filings for Q3 2017.